FDA Approves First Drug Proven to Slow Progression of Alzheimer's Disease

The FDA has granted full approval to the Alzheimer's drug Leqembi, the first drug with clear evidence that it can slow cognitive decline in people with early stages of the disease.
Medicare coverage for Leqembi will now allow more patients access to the drug, which provides people in the early stages of Alzheimer's more time to maintain their independence and quality of life.
Leqembi targets amyloid beta, a protein involved in the progression of Alzheimer's, and is administered through IV infusions every two weeks.
Clinical trials showed Leqembi slowed cognitive decline by 27% compared to a placebo, though it can cause side effects like brain swelling and hemorrhaging.
The approval of Leqembi is a milestone for Alzheimer's treatment and may encourage investment in other experimental therapies currently in development.